Repository logo
 
Publication

The GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 24 weeks. Both clinical (dactylitis severity score and the Leeds dactylitis index) and imaging (high resolution magnetic resonance imaging), among others, were assessed as outcomes. The main objective of GO-DACT is to provide evidence to improve the treatment algorithm and care of psoriatic arthritis patients with active dactylitis. In this manuscript we describe the GO-DACT protocol and general concepts of the methodology of this trial.

dc.contributor.authorVieira-Sousa, E
dc.contributor.authorCanhão, H
dc.contributor.authorAlves, P
dc.contributor.authorRodrigues, AM
dc.contributor.authorTeixeira, F
dc.contributor.authorTavares-Costa, J
dc.contributor.authorBernardo, A
dc.contributor.authorPimenta, S
dc.contributor.authorPimentel-Santos, .
dc.contributor.authorGomes, JL
dc.contributor.authorAguiar, R
dc.contributor.authorVideira, T.
dc.contributor.authorPinto, P
dc.contributor.authorCatita, C
dc.contributor.authorSantos, H
dc.contributor.authorBorges, J.
dc.contributor.authorSequeira, G.
dc.contributor.authorRibeiro, C.
dc.contributor.authorTeixeira, L.
dc.contributor.authorÁvila-Ribeiro, P
dc.contributor.authorMartins, FM
dc.contributor.authorRibeiro, RM
dc.contributor.authorFonseca, JE
dc.date.accessioned2018-10-22T00:08:05Z
dc.date.available2018-10-22T00:08:05Z
dc.date.issued2018
dc.description.abstractThe GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 24 weeks. Both clinical (dactylitis severity score and the Leeds dactylitis index) and imaging (high resolution magnetic resonance imaging), among others, were assessed as outcomes. The main objective of GO-DACT is to provide evidence to improve the treatment algorithm and care of psoriatic arthritis patients with active dactylitis. In this manuscript we describe the GO-DACT protocol and general concepts of the methodology of this trial.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationActa Reumatol Port. 2018 Apr-Jun;43(2):80-92pt_PT
dc.identifier.issn0303-464X
dc.identifier.urihttp://hdl.handle.net/10400.26/24424
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSociedade Portuguesa de Reumatologiapt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/pt_PT
dc.subjectDactylitispt_PT
dc.subjectTreatment Algorithmpt_PT
dc.subjectPsoriatic Arthritispt_PT
dc.titleThe GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 24 weeks. Both clinical (dactylitis severity score and the Leeds dactylitis index) and imaging (high resolution magnetic resonance imaging), among others, were assessed as outcomes. The main objective of GO-DACT is to provide evidence to improve the treatment algorithm and care of psoriatic arthritis patients with active dactylitis. In this manuscript we describe the GO-DACT protocol and general concepts of the methodology of this trial.pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceLisboapt_PT
oaire.citation.endPage92pt_PT
oaire.citation.issue2pt_PT
oaire.citation.startPage80pt_PT
oaire.citation.titleActa Reumatológica Portuguesapt_PT
oaire.citation.volume43pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
11 - The GO-DACT protocol.pdf
Size:
4.09 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description: